Literature DB >> 18649992

Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results.

Giorgio Pizzocaro1, Nicola Nicolai, Angelo Milani.   

Abstract

BACKGROUND: Chemotherapy is emerging in the management of advanced penile cancer.
OBJECTIVE: To evaluate the therapeutic activity of taxanes (T) in combination with cisplatin-fluorouracil (PF) for salvage of primarily unresectable or relapsed nodal metastases from squamous cell carcinoma (SCC) of the penis. DESIGN, SETTING, AND PARTICIPANTS: Six consecutive patients were treated at Istituto Nazionale Tumori (INT), Milano, with neoadjuvant paclitaxel, cisplatin, and 5-fluorouracil (TPF) for unresectable (two cases) or recurrent nodal metastases (four cases) from SCC of the penis from 2004 to 2006. Informed consent was given by all patients. INTERVENTION: Four courses of neoadjuvant TPF were to be given before salvage surgery. MEASUREMENTS: Patients underwent computed tomography (CT) scans before starting chemotherapy, after two courses, and at the end of chemotherapy. Lymph node dissection was to be performed in responsive patients. RESULTS AND LIMITATIONS: Two patients received more than four courses: Both had pathologically documented complete remission, and they are alive and disease free >2 yr after chemotherapy. The other four patients received only two courses. The first patient had subjective intolerance to TPF: He underwent early postchemotherapy radical lymph node dissection, which documented >90% tumour necrosis: He is alive and disease free 46 mo after starting chemotherapy. Of the other three patients, one was not responsive, changed therapy, and died within 4 mo. The other two had a clinical complete remission after the first two courses. Both refused to complete chemotherapy, and they relapsed after 10 and 4 mo. Limitations are the small number of patients and protocol violation in three cases.
CONCLUSIONS: TPF chemotherapy for unresectable or recurrent nodal metastases from SCC of the penis is promising, and the standard four courses of therapy are to be completed in responding patients. A larger series is necessary to confirm preliminary results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18649992     DOI: 10.1016/j.eururo.2008.07.014

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  35 in total

Review 1.  [The significance of lymphadenectomy in the management of penile cancer].

Authors:  M Angerer-Shpilenya; G Jakse
Journal:  Urologe A       Date:  2009-01       Impact factor: 0.639

2.  [Neoadjuvant, adjuvant and palliative chemotherapy of penile cancer].

Authors:  C Protzel; A K Seitz; O W Hakenberg; M Retz
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

3.  18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results.

Authors:  Niels M Graafland; Renato A Valdés Olmos; Hendrik J Teertstra; J Martijn Kerst; Andries M Bergman; Simon Horenblas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-27       Impact factor: 9.236

4.  Multiple cutaneous metastasis from carcinoma of the penis-report of two cases.

Authors:  Joydeep Purkayastha
Journal:  Indian J Surg Oncol       Date:  2013-01-20

5.  Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

Authors:  Suzanne Richter; J Dean Ruether; Lori Wood; Christina Canil; Patricia Moretto; Peter Venner; Joel Gingerich; Urban Emmenegger; Andrea Eisen; Pawel Zalewski; Anthony Joshua; Som Dave Mukherjee; Daniel Heng; Piotr Czaykowski; Denis Soulieres; Norman Blais; Ricardo Rendon; Neil Fleshner; Juanita M Crook; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

Review 6.  Challenges and controversies in the management of penile cancer.

Authors:  Majid Shabbir; Oliver Kayes; Suks Minhas
Journal:  Nat Rev Urol       Date:  2014-11-18       Impact factor: 14.432

Review 7.  Penile cancer: current therapy and future directions.

Authors:  G Sonpavde; L C Pagliaro; C Buonerba; T B Dorff; R J Lee; G Di Lorenzo
Journal:  Ann Oncol       Date:  2013-01-04       Impact factor: 32.976

8.  [Penile carcinoma: diagnosis and therapy].

Authors:  C Protzel; O W Hakenberg
Journal:  Urologe A       Date:  2013-01       Impact factor: 0.639

9.  [The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics].

Authors:  C Protzel; S Ruppin; S Milerski; K-J Klebingat; O W Hakenberg
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

10.  [Characterization of the EGF receptor status in penile cancer : retrospective analysis of the course of the disease in 45 patients].

Authors:  C Börgermann; K J Schmitz; S Sommer; H Rübben; S Krege
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.